Centene said premium and service revenues for 2024 were $145.5 billion, representing 4% growth, diluted EPS was $6.31 compared to $4.95 for 2023, and adjusted diluted EPS was $7.17 compared to $6.68 for 2023.

1. 01

   Centene said premium and service revenues for 2024 were $145.5 billion, representing 4% growth, diluted EPS was $6.31 compared to $4.95 for 2023, and adjusted diluted EPS was $7.17 compared to $6.68 for 2023.

2. 02

   The company said the HBR for 2024 was 88.3%, compared to 87.7% for 2023, and cited higher acuity in Medicaid resulting from the redetermination process and Medicare Star rating impacts as factors for the increase.

3. 03

   Centene said operating cash flows for 2024 were $154 million, compared to $8.1 billion for 2023, and cited an increase in pharmacy receivables driven by pharmacy rebate remittance timing, a decrease in net risk adjustment payables and higher state premium receivables for recent rate increases as factors.

4. 04

   The company said it repurchased 42.0 million shares of common stock for $3.0 billion under the stock repurchase program in 2024 and had $2.2 billion remaining under the program as of December 31, 2024.

Key figures

Fiscal year ended December 31, 2024

Operating income

$3.2B

Net income

$3.3B

EPS

$6.31

Gross profit

$17.1B

Operating cash flow

$154M

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.